RxDoctor Payments Data

Robert Fleury, MD

Psychiatry · Pinehurst, NCNPI 1467495903

Payments from drug & device makers

$1,345in general payments, 2019–2025

Across 80 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$354
  • Alkermes, Inc.$211
  • Sunovion Pharmaceuticals Inc.$102
  • Takeda Pharmaceuticals U.S.A., Inc.$101
  • Johnson & Johnson$92
  • Shire North American Group Inc$80
  • plus $405 from 11 others

What the payments were for

  • Food & beverage$1,345100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,345 in reported general payments places this provider in the 75th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$16,216
Medicare patients
42
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine24$151,407
VraylarCariprazine Hcl14$20,727
SuboxoneBuprenorphine Hcl/Naloxone Hcl17$13,768
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl28$6,307
Desvenlafaxine Succinate ErDesvenlafaxine Succinate78$2,782
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine33$1,568
Duloxetine Hcl54$1,541
Buprenorphine Hcl27$1,086
Aripiprazole35$675
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine19$666
Gabapentin37$584
Clonazepam74$568
Alprazolam128$514
Carbamazepine13$496
Venlafaxine Hcl ErVenlafaxine Hcl42$456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$19$151,40724 claims
AbbVieVraylar$66$20,72714 claims
Indivior Inc.Suboxone$75$13,76817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Pinehurst

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →